Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Brensocatib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    New Positive Data From Brensocatib Study To Be Presented At Conference
    New Positive Data From Brensocatib Study To Be Presented At Conference

    03 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/additional-positive-data-from-pivotal-aspen-study-of-brensocatib-in-patients-with-bronchiectasis-to-be-presented-at-the-7th-world-bronchiectasis-conference-302188927.html

    PR NEWSWIRE
    03 Jul 2024
    Share Share
    Insmed shares double as lung drug data convince Wall Street
    Insmed shares double as lung drug data convince Wall Street

    29 May 2024

    // BIOPHRAMADIVE

    https://www.biopharmadive.com/news/insmed-aspen-brensocatib-bronchiectasis-trial-results/717222/

    BIOPHRAMADIVE
    29 May 2024
    Share Share
    Insmed: Positive Topline ASPEN Data For Brensocatib In Bronchiectasis
    Insmed: Positive Topline ASPEN Data For Brensocatib In Bronchiectasis

    28 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/insmed-announces-positive-topline-results-from-landmark-aspen-study-of-brensocatib-in-patients-with-bronchiectasis-302156279.html

    PR NEWSWIRE
    28 May 2024
    Share Share
    Insmed Completes Enrollment of Patients in Phase 3 ASPEN Study of Brensocatib
    Insmed Completes Enrollment of Patients in Phase 3 ASPEN Study of Brensocatib

    31 Mar 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/insmed-completes-enrollment-of-adult-patients-in-phase-3-aspen-study-of-brensocatib-in-bronchiectasis-301786434.html

    PR NEWSWIRE
    31 Mar 2023
    Share Share
    Insmed Announces Initiation of Phase 3 ASPEN Study of Brensocatib in Patients
    Insmed Announces Initiation of Phase 3 ASPEN Study of Brensocatib in Patients

    02 Dec 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/insmed-announces-initiation-of-phase-3-aspen-study-of-brensocatib-in-patients-with-bronchiectasis-301183121.html

    PRNEWSWIRE
    02 Dec 2020
    Share Share
    Phase 2 WILLOW Study of Brensocatib in Patients shows positive results
    Phase 2 WILLOW Study of Brensocatib in Patients shows positive results

    07 Sep 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/new-england-journal-of-medicine-publishes-positive-results-from-phase-2-willow-study-of-brensocatib-in-patients-with-non-cystic-fibrosis-bronchiectasis-301124508.html

    PRNEWSWIRE
    07 Sep 2020
    Share Share